TABLE 4.
Noninterventional studies selected for evaluations.
| CDA guidelines sections (items) | Ustekinumab in IBD a | Ixekizumab in PsA | Dimethyl fumarate in MS a | Tofacitinib in RA a | Erenumab in migraine | |||||
|---|---|---|---|---|---|---|---|---|---|---|
| Reporting scores | NR | NA | NR | NA | NR | NA | NR | NA | NR | NA |
| 1. Study design and research questions [11] | 0 | 1 | 2 | 1 | 3 | 1 | 3 | 1 | 3 | 1 |
| 2. Setting and content [4] | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 0 | 1 |
| 3. Data specifications, access, cleaning methods and linkage [10] | 1 | 8 | 2 | 8 | 2 | 8 | 2 | 8 | 0 | 8 |
| 4. Data Sources, data dictionary and variables [12] | 1 | 2 | 6 | 2 | 4 | 3 | 4 | 3 | 2 | 2 |
| 5. Participants [3] | 3 | 2 | 6 | 2 | 2 | 2 | 3 | 2 | 4 | 2 |
| 6. Exposure definitions and comparators [8] | 0 | 5 | 0 | 5 | 0 | 5 | 2 | 5 | 0 | 5 |
| 7. Outcomes [7] | 2 | 1 | 1 | 1 | 0 | 1 | 1 | 1 | 1 | 1 |
| 8. Bias, confounding, and effect modifiers or subgroup effects [11] | 9 | 0 | 11 | 0 | 11 | 0 | 11 | 0 | 10 | 0 |
| 9. Statistical Methods [5] | 7 | 0 | 10 | 0 | 8 | 0 | 6 | 0 | 9 | 0 |
| 10. Study findings [8] | 5 | 0 | 6 | 0 | 5 | 0 | 3 | 0 | 6 | 0 |
| 11. Interpretation and generalizability [7] | 2 | 0 | 2 | 0 | 2 | 0 | 2 | 0 | 3 | 0 |
| 12. Limitations [2] | 0 | 0 | 1 | 0 | 1 | 0 | 1 | 0 | 1 | 0 |
| Total | 31 | 19 | 48 | 19 | 39 | 20 | 39 | 20 | 39 | 19 |
NR, Not Reported; NA, Not Applicable.
a
With Supplementary Data published.